Abstract: Bladder cancer is the first common urogenital malignant tumor among the Chinese men, and the incidence is trending to rapidly ascend. Rho GDP dissociation inhibitor 2(RhoGDI2) is found to be a new metastasis suppressor factor of bladder cancer in recent years. Previous studies have confirmed that RhoGDI2 protein can inhibit bladder cancer metastases, and its molecular mechanism maybe regulate the downstream gene of erbB1/EGFR tyrosine kinase receptor, calcium binding protein S100A4, p53 and MTSS1 which stop tumor progression. RhoGDI2 gene deletion also is a poor prognostic factor in patients with bladder cancer. In conclusion, expression of RhoGDI2 gene can be as a signal for diagnosis of patients with bladder cancer prone to metastasis. RhoGDI2 is expected to be a therapeutic molecules inhibiting bladder cancer. In this paper,we give an overview of RhoGDI2 function in bladder carcinoma. These include the RhoGDI2 discovery, RhoGDI2 expression in pathological specimens, and the molecular mechanism that RhoGDI2 inhibits the metastasis.